CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma.
SOHO State of the Art Updates and Next Questions | From Biology to Therapy: Progress in Hodgkin Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
经典霍奇金淋巴瘤（HL）是一种独特的淋巴系统恶性肿瘤，其恶性细胞仅占肿瘤总细胞构成的1%至2%。过去20年间，基于新型靶向疗法的出现，HL的治疗发生了巨大变化。包括程序性死亡-1（PD-1）抑制剂、抗体药物偶联物如brentuximab vedotin、双特异性抗体以及嵌合抗原受体（CAR）T细胞疗法在内的新型药物，已在一线以及复发/难治性（R/R）背景下塑造了HL的管理格局。其中一些药物已被纳入治疗算法，而另一些目前正在研究中，并显示出令人鼓舞的结果。本综述重点强调构成HL治疗基础的潜在肿瘤生物学，并回顾一些新兴和已确立的新型疗法。
Classic Hodgkin lymphoma (HL) is a unique lymphoid malignancy where the malignant cells comprise only 1% to 2% of the total tumor cellularity. Over the past 2 decades, the treatment of HL has evolved drastically based on the advent of novel targeted therapies. Novel agents including programmed death-1 (PD-1) inhibitors, antibody-drug conjugates such as brentuximab vedotin, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapies have served to shape the management of HL in the frontline as well as the relapsed and refractory (R/R) setting.
Some of these agents have been incorporated into treatment algorithms, while others are currently under investigation demonstrating promising results. This review focuses on highlighting the underlying tumor biology forming the basis of therapeutics in HL, and reviews some of the emerging and established novel therapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
